Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by venture009on Feb 05, 2024 1:02pm
416 Views
Post# 35863375

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:ONCY January 2024 slide deck - over 120 panc pts studied

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:ONCY January 2024 slide deck - over 120 panc pts studiedNoteable this is suppose to be a discussion site. Some of us have legitimate concerns when the sp continues to decline and ONC's available cash is now below 12 months and they seem to be sending mixed signals, which the investment community punishes the sp. People that have an investment have as much right to voice their concern as your continually pushing hypothetical scenarios and you have not been correct over the years. Your paranoia that all people questioning the current state are short sellers and only interested in seeing the company decline. is complete nonsense. Personally I have lost a small fortune over the 23 years I have been invested and I completly blame the management for screwing this up and it seems they continue to do so. My disappointment in this company is beyond words and yet I still feel the therapy should, at some point be used to treat this difficult disease. But like many I fear management will find a way to complete destroy it. The number of small biotechs filing for Chapter 11 protection is many and this has to be in the back of everyones mind at this stage. 
On a another note, of all the years I have been invested, I believe this is the first time a financing hasn't been initiated when cash is less than 12 months. 
<< Previous
Bullboard Posts
Next >>